{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-002428","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2026-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.537306+00:00","generated_at":"2026-05-16T10:08:14.853937+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Hepion Pharmaceuticals names Kaouthar Lbiati CEO effective Jan 8, 2026; salary $350K","bullets":["Dr. Kaouthar Lbiati appointed CEO effective Jan 8, 2026, per Board approval on Jan 13, 2026.","Annual base salary $350,000; $50,000 deferred until equity financing ≥$3M, termination, or change of control.","Annual cash bonus target 35% of base salary based on Board-set goals.","Change-of-control bonus: 3% of enterprise value if ≥$5M.","Severance: 6 months base plus bonus upon termination without cause or good reason; equity acceleration provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-002428","json":"https://secwatch.observer/filing/0001493152-26-002428.json","markdown":"https://secwatch.observer/filing/0001493152-26-002428.md","text":"https://secwatch.observer/filing/0001493152-26-002428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226002428/0001493152-26-002428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226002428/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:08:14.853937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}